Status:
COMPLETED
Implementing a Virtual Tobacco Treatment for Cancer Patients in Community Oncology Practices
Lead Sponsor:
ECOG-ACRIN Cancer Research Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Carcinoma In Situ
Current Smoker
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
This phase II trial studies how well smoking cessation treatment plans work in tobacco-dependent cancer patients when delivered virtually as part of their cancer care in community oncology practices. ...
Detailed Description
PRIMARY OBJECTIVE: I. To compare the proportions of participants in the Enhanced Usual Care (EUC) and Virtual Tobacco Treatment (VIT) study arms with biochemically-verified 7-day point-prevalence abs...
Eligibility Criteria
Inclusion
- STAFF ELIGIBILITY CRITERIA:
- Must be English speaking.
- Must be employed at NCI Community Oncology Research Program (NCORP) site for at least three months.
- PATIENT ELIGIBILITY CRITERIA STEP 0:
- Patient presenting with any type of cancer with a date of diagnosis within the past 4 months. Recurrence, diagnosed within the last 4 months, of tumors in patients with past cancer diagnoses will be considered eligible. Patients with a new primary cancer, diagnosed within the last 4 months, who have been treated previously for other types of cancer will also be considered eligible. ?In situ? cancers, diagnosed within the past 4 months, will also be considered eligible.
- Patient must be a current smoker. Current smoker is defined as any cigarette smoking (even a puff) in the past 30 days.
- Patient must be fluent in both, written and spoken, English or both, written and spoken, Spanish.
- Patient must have telephone, e-mail access, and have access to the internet with a camera-enabled device (e.g., smartphone, tablet, computer, laptop with a webcam/camera)
- NOTE: The restriction to those with web and e-mail access is based on the primary intention of the study; to assess the implementation of the virtual intervention in the NCORP network.
- ELIGIBILITY CRITERIA STEP 1: Patient must still meet all criteria outlined in step 0.
- ELIGIBILITY STEP 2 (RANDOMIZATION): Patient must have completed baseline survey in Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) Cancer Research Group Systems for Easy Entry of Patient Reported Outcomes (EASEEPRO) within 1 month (30 days) of the date of informed consent (Step 1).
Exclusion
- Patient has an Eastern Cooperative Oncology Group (ECOG) performance status of 3 or above, or is deemed medically unable to participate by study investigators or oncology clinician (i.e., referral to hospice).
- Patient has no intention to receive their cancer care or monitoring at an NCORP community cancer site.
Key Trial Info
Start Date :
August 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2023
Estimated Enrollment :
306 Patients enrolled
Trial Details
Trial ID
NCT03808818
Start Date
August 1 2019
End Date
December 31 2023
Last Update
March 18 2025
Active Locations (42)
Enter a location and click search to find clinical trials sorted by distance.
1
Alaska Women's Cancer Care
Anchorage, Alaska, United States, 99508
2
Katmai Oncology Group
Anchorage, Alaska, United States, 99508
3
Northside Hospital
Atlanta, Georgia, United States, 30342
4
Augusta University Medical Center
Augusta, Georgia, United States, 30912